Compass Pathways Q1 net loss $17.9M; cash $260.1M; phase 3 top-line data expected late June

COMPASS Pathways plc

2025-Q1 EPS reported -$0.24

Net loss $17.9M ($0.24 diluted EPS) vs $35.2M ($0.55) in Q1 2024; includes $19.5M non-cash gain on warrant liabilities.
R&D expenses $30.9M, up 24% YoY due to advancing COMP360 phase 3 trials; G&A $18.7M, up 36%.
Cash $260.1M at Mar 31, 2025, vs $165.1M at Dec 31, 2024; net cash raised $140.4M in Q1.
Top-line 6-week data from COMP005 phase 3 in TRD expected late June 2025; COMP006 26-week data H2 2026.
Full-year 2025 net cash used in ops guided at $120M-$145M; cash expected to fund through COMP006 readout.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.